– USA, NV – ALT5 Sigma Corporation (NASDAQ: ALTS / FRA: 5AR1), a fintech specializing in turnkey, crypto-related solutions for institutions and merchants, welcomes Zach Witkoff, Co-Founder and CEO of World Liberty Financial, Inc., as Chairman of its Board of Directors. His appointment is part of a broader expansion of the leadership team, including the addition of Eric Trump as a Board Director with Zak Folkman as Board Observer.
About ALT5 Sigma Corporation
ALT5 Sigma Corporation is a fintech, providing next-generation blockchain-powered technologies for tokenization, trading, clearing and settlement, payment, and safekeeping of digital assets. ALT5 has been a constituent of the Russell Microcap Index since June 28, 2024.
Founded in 2018, ALT5 Sigma, Inc. enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The Company has processed over $5 billion in cryptocurrency transactions since its inception.
ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.
The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for the treatment of CRPS.
For more information: https://www.alt5sigma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.